Browse > Article
http://dx.doi.org/10.4014/jmb.2111.11026

A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization  

Mattoo, Sameer-ul-Salam (Korea Zoonosis Research Institute, Department of Bioactive Material Science and Genetic Engineering Research Institute, Jeonbuk National University)
Myoung, Jinjong (Korea Zoonosis Research Institute, Department of Bioactive Material Science and Genetic Engineering Research Institute, Jeonbuk National University)
Publication Information
Journal of Microbiology and Biotechnology / v.31, no.12, 2021 , pp. 1601-1614 More about this Journal
Abstract
To overcome the ongoing COVID-19 pandemic, vaccination campaigns are the highest priority of majority of countries. Limited supply and worldwide disproportionate availability issues for the approved vaccines, together with concerns about rare side-effects have recently initiated the switch to heterologous vaccination, commonly known as mixing of vaccines. The COVID-19 vaccines are highly effective in the general population. However, none of the vaccines is 100% efficacious or effective, with variants posing more challenges, resulting in breakthrough cases. This review summarizes the current knowledge of immune responses to variants of concern (VOC) and breakthrough infections. Furthermore, we discuss the scope of heterologous vaccination and future strategies to tackle the COVID-19 pandemic, including fractionation of vaccine doses and alternative route of vaccination.
Keywords
SARS-CoV-2; variants of concern; heterologus vaccination; hybrid immunity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. 2021. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 27: 1525-1529.   DOI
2 Ostadgavahi AT, Booth R, Sisson G, McMullen N, Warhuus M, Robertson P, et al. 2021. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response. J. Infect. Dev. Ctries. 15: 653-656.   DOI
3 Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586: 589-593.   DOI
4 Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. 2021. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New Engl. J. Med. 385: 875-884.   DOI
5 Crotty S. 2021. Hybrid immunity. Science 372: 1392-1393.   DOI
6 Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. 2021. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 25: eabg9175.
7 Myoung J, Min K. 2019. Dose-dependent inhibition of melanoma differentiation-associated gene 5-mediated activation of type I interferon responses by methyltransferase of hepatitis E virus. J. Microbiol. Biotechnol. 29: 1137-1143.   DOI
8 Myoung J, Lee JY, Min KS. 2019. Methyltransferase of a cell culture-adapted hepatitis E inhibits the MDA5 receptor signaling pathway. J. Microbiol. 57: 1126-1131.   DOI
9 Lee JY, Bae S, Myoung J. 2019. Middle East respiratory syndrome coronavirus-encoded accessory proteins impair MDA5-and TBK1-mediated activation of NF-kappaB. J. Microbiol. Biotechnol. 29: 1316-1323.   DOI
10 Lee J, Bae S, Myoung J. 2019. Generation of full-length infectious cDNA clones of middle East respiratory syndrome coronavirus. J. Microbiol. Biotechnol. 29: 999-1007.   DOI
11 WHO. 2021. Interim statement on dose-sparing strategies for COVID-19 vaccines (fractionated vaccine doses). Available from https://www.who.int/news/item/10-08-2021-interim-statement-on-dose-sparing-strategies-for-covid-19-vaccines-(fractionated-vaccine-doses). Accessed Oct. 21, 2021.
12 Wu JT, Peak CM, Leung GM, Lipsitch M. 2016. Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet (London, England) 388: 2904-2911.   DOI
13 Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. 2020. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20: 615-632.   DOI
14 Szabo PA, Miron M, Farber DL. 2019. Location, location, location: Tissue resident memory T cells in mice and humans. Sci. Immunol. 4: eaas9673-eaas9673.   DOI
15 Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. 2020. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183: 169-184.e113.   DOI
16 Pizzolla A, Wakim LM. 2019. Memory T cell dynamics in the lung during influenza virus infection. J. Immunol. 202: 374-381.   DOI
17 Niyas VKM, Arjun R. 2021. Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine. QJM: Int. J. Med. 114: 757-758.   DOI
18 Lange B, Gerigk M, Tenenbaum T. 2021. Breakthrough infections in BNT162b2-vaccinated health care workers. N. Engl. J. Med. 385: 1145-1146.   DOI
19 Edara V-V, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. 2021. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. New Engl. J. Med. 385: 664-666.   DOI
20 Hoffmann M, Hofmann-Winkler H, Kruger N, Kempf A, Nehlmeier I, Graichen L, et al. 2021. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 36: 109415.   DOI
21 Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. 2021. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 6: e335-e345.   DOI
22 Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, et al. 2021. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. New Engl. J. Med. 385: 951-953.   DOI
23 Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. 2021. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27: 1379-1384.   DOI
24 Duerr R, Dimartino D, Marier C, Zappile P, Wang G, Lighter J, et al. 2021. Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J. Clin. Invest. 131: e152702.   DOI
25 Ioannou P, Karakonstantis S, Astrinaki E, Saplamidou S, Vitsaxaki E, Hamilos G, et al. 2021. Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. Infect. Dis. 53: 876-879.   DOI
26 Martinot M, Carnein S, Kempf C, Gantner P, Gallais F, Fafi-Kremer S. 2021. Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. Clin. Microbiol. Infect. 27: 1537-1539.   DOI
27 Lee JY, Kim SJ, Myoung J. 2019. Middle east respiratory syndrome coronavirus-encoded ORF8b inhibits RIG-I-like receptors in a differential mechanism. J. Microbiol. Biotechnol. 29: 2014-2021.   DOI
28 Mallapaty S. 2021. A blood marker predicts who gets 'breakthrough' COVID. Nature doi: 10.1038/d41586-021-02096-3. Online ahead of print.   DOI
29 Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. 2020. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586: 567-571.   DOI
30 Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. 2021. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2: 100355-100355.   DOI
31 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. 2021. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New Engl. J. Med. 384: 2092-2101.   DOI
32 Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. 2020. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J. Microbiol. Biotechnol. 30: 313-324.   DOI
33 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. 2021. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England J. Med. 384: 1412-1423.   DOI
34 Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. 2021. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med. 27: 1614-1621.   DOI
35 Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F, et al. 2021. Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. Vaccines 9: 857-857.   DOI
36 Ngueyen TTN, Kim SJ, Lee JY, Myoung J. 2019. Zika virus proteins NS2A and NS4A are major antagonists that reduce IFN-beta promoter activity induced by the MDA5/RIG-I signaling pathway. J. Microbiol. Biotechnol. 29: 1665-1674.   DOI
37 Our World in D. 2021. Coronavirus (COVID-19) Vaccinations - Statistics and Research. Available from https://ourworldindata.org/covid-vaccinations. Accessed Oct. 21, 2021.
38 WHO. 2021. Tracking SARS-CoV-2 variants. Available from https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed Oct. 20, 2021.
39 Swanson PA, Padilla M, Hoyland W, McGlinchey K, Fields PA, Bibi S, et al. 2021. T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire. medRxiv. doi: 10.1101/2021.06.17.21259027. Preprint   DOI
40 Agerer B, Koblischke M, Gudipati V, Montano-Gutierrez LF, Smyth M, Popa A, et al. 2021. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. Sci. Immunol. 6: eabag6461.
41 Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. 2021. Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England) 6736: 21-24.
42 Ulhaq ZS, Soraya GV, Indriana K. 2021. Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine. Indian J. Med. Microbiol. 39: 562-563.   DOI
43 Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science 372: eabg3055.   DOI
44 Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19: 409-424.   DOI
45 Abu-Raddad LJ, Chemaitelly H, Butt AA. 2021. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. New England J. Med. 385: 187-189.   DOI
46 Chen Y, Yin S, Tong X, Tao Y, Ni J, Pan J, et al. 2021. Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine. Clin. Microbiol. Infect. S1198-743X(21)00605-4. doi: 10.1016/j.cmi.2021.10.006.   DOI
47 Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. 2021. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 9: 999-1009.   DOI
48 Liu G, Carter B, Gifford DK. 2021. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Systems 12: 102-107.e104.   DOI
49 Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. 2021. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol. 6: eabj1750-eabj1750.   DOI
50 Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. 2021. Covid-19 breakthrough infections in vaccinated health care workers. New Engl. J. Med. 385: 1145-1146.   DOI
51 Wise J. 2021. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 372: n699-n699.   DOI
52 Borobia AM, Carcas AJ, Perez-Olmeda M, Castano L, Bertran MJ, Garcia-Perez J, et al. 2021. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 398: 121-130.   DOI
53 Richardson CD. 2021. Heterologous ChAdOx1-nCoV19?NT162b2 vaccination provides superior immunogenicity against COVID-19. Lancet Respir. Med. 314: 1936-1938.
54 Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. 2021. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 27: 1530-1535.   DOI
55 Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. 2021. Vaccine breakthrough infections with SARS-CoV-2 variants. New Engl. J. Med. 384: 2212-2218.   DOI
56 Chvatal-Medina M, Mendez-Cortina Y, Patino PJ, Velilla PA, Rugeles MT. 2021. Antibody responses in COVID-19: A Review. Front. Immunol. 12: 633184.   DOI
57 Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184: 2201-2211.e2207.   DOI
58 Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184: 4220-4236.e4213.   DOI
59 Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. 2021. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance 26: 2100509.
60 Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. 2021. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372: 815-821.   DOI
61 Sette A, Crotty S. 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184: 861-880.   DOI
62 Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, et al. 2020. SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential. Cell Rep. Med. 1: 100081-100081.   DOI
63 Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. 2021. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593: 130-135.   DOI
64 Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. 2021. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England) 398: 856-869.   DOI
65 Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. 2021. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184: 2384-2393.e2312.   DOI
66 Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. 2021. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397: 2331-2333.   DOI
67 Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, et al. 2021. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J. Virol. 95: e0131321.   DOI
68 Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. 2021. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect. Dis. 21: 1352-1354.   DOI
69 Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. 2021. Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. Cell 184: 2348-2361. e2346.   DOI
70 Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. 2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5: eabd2071-eabd2071.   DOI
71 Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. 2020. COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. Nature 586: 594-599.   DOI
72 Koutsakos M, Lee WS, Wheatley AK, Kent SJ, Juno JA. 2021. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. J. Leukoc. Biol. 10.1002/JLB.5MR0821-464R.   DOI
73 Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J-B, Olsson A, et al. 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183: 158-168. e114.   DOI
74 Schulien I, Kemming J, Oberhardt V, Wild K, Seidel LM, Killmer S, et al. 2021. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. Nat. Med. 27: 78-85.   DOI
75 Cowling BJ, Lim WW, Cobey S. 2021. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nat. Med. 27: 1321-1323.   DOI
76 Tan C-W, Chia W-N, Young BE, Zhu F, Lim B-L, Sia W-R, et al. 2021. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N. Engl. J. Med. 385: 1401-1406.   DOI
77 Selingerova I, Valik D, Gescheidtova L, Sramek V, Cermakova Z, Zdrazilova-Dubska L. 2021. Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG by MAGLUMI. J. Med. Virol. 93: 1805-1809.   DOI
78 Lee JY, Bae S, Myoung J. 2019. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-beta promoter activation: its implication for vaccine design. J. Microbiol. 57: 803-811.   DOI
79 Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. 2021. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21: 626-636.   DOI
80 Callaway E. 2021. COVID vaccine boosters: the most important questions. Nature 596: 178-180.   DOI
81 Jeyanathan M, Yao Y, Afkhami S, Smaill F, Xing Z. 2018. New Tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol. 39: 419-433.   DOI
82 Brinkley-Rubinstein L, Peterson M, Martin R, Chan P, Berk J. 2021. Breakthrough SARS-CoV-2 infections in prison after vaccination. N. Engl. J. Med. 385: 1051-1052.   DOI
83 Bae S, Lee JY, Myoung J. 2020. Chikungunya virus nsP2 impairs MDA5/RIG-I-mediated induction of NF-kappaB promoter activation: A potential target for virus-specific therapeutics. J. Microbiol. Biotechnol. 30: 1801-1809.   DOI
84 Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. 2021. Serum neutralizing activity elicited by mRNA-1273 vaccine. New Engl. J. Med. 384: 1468-1470.   DOI
85 Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 397: 1351-1362.   DOI
86 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397: 99-111.   DOI
87 Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. 2021. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596: 109-113.   DOI
88 Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J-B, Olsson A, et al. 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183: 158-168.e114.   DOI
89 Gallais F, Velay A, Nazon C, Wendling M-J, Partisani M, Sibilia J, et al. 2021. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg. Infect. Dis. 27: 113-121.   DOI
90 Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. 2021. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir. Med. 9: 918-918.
91 Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. 2021. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms 9: 1542.   DOI
92 Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. 2021. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination. Sci. Immunol. 6: eabi6950.   DOI
93 Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. 2021. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 39: 2791-2799.   DOI
94 Novak N, Tordesillas L, Cabanillas B. 2021. Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int. Rev. Immunol. 1-10.
95 Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. 2021. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 397: 2043-2046.
96 Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra A-B, Khal AA, Coyle PV, et al. 2021. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. Int. J. Infect. Dis. 110: 353-358.   DOI
97 Estofolete CF, Banho CA, Campos GRF, Marques BdC, Sacchetto L, Ullmann LS, et al. 2021. Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronaVac vaccinees in Brazil. Viruses 13: 1237-1237.   DOI
98 Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. 2021. Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine. New Engl. J. Med. 385: 1172-1183.   DOI
99 Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. 2021. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27: 917-924.   DOI
100 Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. 2021. Neutralizing activity of BNT162b2-elicited serum. New Engl. J. Med. 384: 1466-1468.   DOI
101 Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. 2021. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21: 395-404.   DOI
102 WHO. 2017. WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013. Vaccine 35: 5751-5752.   DOI
103 Myoung J, Lee SA, Lee HR. 2019. Beyond viral interferon regulatory factors: Immune evasion strategies. J. Microbiol. Biotechnol. 29: 1873-1881.   DOI
104 Yang J, Zhong M, Hong K, Yang Q, Zhang E, Zhou D, et al. 2021. Characteristics of T-cell responses in COVID-19 patients with prolonged SARS-CoV-2 positivity - a cohort study. Clin. Transl. Immunol. 10: e1259-e1259.
105 Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, et al. 2021. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54: 2133-2142. e2133.   DOI
106 Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. 2020. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183: 996-1012.e1019.   DOI
107 Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. 2021. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596: 276-280.   DOI
108 Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. 2021. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184: 2939-2954.e2939.   DOI
109 Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. 2021. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27: 717-726.   DOI
110 Jalkanen P, Kolehmainen P, Hakkinen HK, Huttunen M, Tahtinen PA, Lundberg R, et al. 2021. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 12: 3991-3991.   DOI
111 Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, et al. 2021. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596: 273-275.   DOI
112 Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al. 2021. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 596: 268-272.   DOI